Bridging the AI Divide in Drug Discovery: Practical Lessons from Capacity Strengthening in Africa
Open Access
- 7 August 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (16) , 19593-19600
Abstract
Artificial Intelligence (AI) has become an integral part of drug discovery in high-income countries. However, these advances have yet to be broadly adopted by research ecosystems in many low- and middle-income countries in Africa, where understudied infectious diseases, compounded by a growing noncommunicable disease burden, cause millions of deaths each year. Given adequate support and appropriate models AI could play a transformative role in under-resourced biomedical research ecosystems in Africa, democratizing drug discovery research. There is an urgent need to invest in building the critical infrastructure, tools, and capacity required. To drive this agenda forward, Ersilia, the H3D Centre, and H3D Foundation with support from the AI2050 program at Schmidt Sciences hosted a series of in-person and online workshops in Africa to grow the AI skills base for medicinal chemistry and enable adoption across regional research hubs. In this perspective article, we discuss the lessons learnt from this program, the fit-for-purpose open-source tools developed, and key considerations for future initiatives.Keywords
Funding Information
- Ministerio de Ciencia, Innovación y Universidades (PID2023-148309OA-I00)
- European Regional Development Fund (PID2023-148309OA-I00)
- Graduate Program in Physics at UNIFAL-MG (G-23-65555)
This publication has 20 references indexed in Scilit:
- Stepping Up Medicinal Chemistry Capabilities in Sub-Saharan Africa: Perspectives from Early Career African Drug Discovery ResearchersJournal of Medicinal Chemistry, 2025
- The future of pharmaceuticals: Artificial intelligence in drug discovery and developmentJournal of Pharmaceutical Analysis, 2025
- Infectious Disease Research Laboratories in Africa Are Not Using AI Yet─Large Language Models May Facilitate AdoptionACS Infectious Diseases, 2024
- Accurate structure prediction of biomolecular interactions with AlphaFold 3Nature, 2024
- Discovery of a structural class of antibiotics with explainable deep learningNature, 2023
- First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in AfricaNature Communications, 2023
- Natural product scores and fingerprints extracted from artificial neural networksComputational and Structural Biotechnology Journal, 2021
- Coloring Molecules with Explainable Artificial Intelligence for Preclinical Relevance AssessmentJournal of Chemical Information and Modeling, 2021
- A Deep Learning Approach to Antibiotic DiscoveryCell, 2020
- A dynamic map for learning, communicating, navigating and improving therapeutic developmentNature Reviews Drug Discovery, 2017